Phase 1, first-in-human, multicenter, open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of KO-2806 when administered as monotherapy and in combination therapy in adult patients with advanced solid tumors

Disease:

Solid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Clear Cell Renal Cell Carcinoma (ccRCC), Renal Cell Carcinoma (Kidney Cancer)

Study phase:

Phase I

Physician name:

David Sanghyun Hong

Department:

Investigational Cancer Therapeutics

For general questions about clinical trials:

1-866-379-1063